Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China

Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China

ObjectiveWe aimed to evaluate the cost-effectiveness of camrelizumab plus chemotherapy compared with chemotherapy alone as the first-line treatment for patients with metastatic or advanced non-squamous non-small cell lung cancer (NSCLC) without targetable epidermal growth factor receptor or anaplast...

Full description

Bibliographic Details
Main Authors: Hongbin Dai, Wenyue Wang, Xin Fan, Yongfa Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Medicine
Subjects:
non-small cell lung cancer
cost-effectiveness
camrelizumab
partitioned survival analysis
China
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1122731/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1122731/full

Similar Items